Nanobiotix

NANOFR0011341205

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.

Filings

63 filings

All Inside information63 Voting rights and capital32 Threshold crossing29 Quarterly financial information5 Earnings release4 Annual financial report4 Universal registration document2 Tender offer2

02/06/2026
Nanobiotix Joins the Euronext Tech Leaders Index
Inside informationFR
26/05/2026
NANOBIOTIX Announces Closing of Global Offering
Inside informationFR
22/05/2026
NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Inside informationFR
21/05/2026
NANOBIOTIX annonce les modalites definitives de son offre globale sursouscrite a hauteur de 85 millions d’euros
Inside informationFrench
21/05/2026
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Inside information
21/05/2026
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
Inside informationFR
21/05/2026
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
Inside informationFR
21/05/2026
Nanobiotix Announces Launch of Global Follow-On Offering
Inside informationFR
17/05/2026
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Inside informationFR
04/05/2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
Inside informationFR
20/04/2026
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Inside informationFR
30/03/2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Inside informationFR
26/03/2026
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
Inside information
25/02/2026
NANOBIOTIX participera à plusieurs conférences investisseurs en mars
Inside informationFrench
15/12/2025
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Inside informationFR
13/11/2025
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Inside informationFR
11/11/2025
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Inside informationFR
03/11/2025
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
Inside informationFR
31/10/2025
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Inside informationFR
24/10/2025
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
Inside informationFR
01/10/2025
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Inside informationFR
30/09/2025
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Inside information
17/09/2025
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Inside informationFR
02/09/2025
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Inside informationFR
07/07/2025
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
Inside informationFR
28/05/2025
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Inside informationFR
12/05/2025
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Inside informationFR
05/05/2025
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Inside informationFR
30/04/2025
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Inside informationFR
31/03/2025
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Inside information
27/03/2025
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Inside informationFR
20/03/2025
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Inside informationFR
17/03/2025
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Inside informationFR
29/01/2025
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
Inside information
21/01/2025
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Inside informationFR

About

ISIN: FR0011341205
Ticker: NANO
LEI: 969500667RSYIH8YL895
Founded: 2003
Country of registration: FR
Last filing: 30/07/2026, 22:15

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive